These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32188898)

  • 1. Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth.
    Lu PJ; Tucker JD; Branch EK; Guo F; Blaeser AR; Lu QL
    Sci Rep; 2020 Mar; 10(1):4935. PubMed ID: 32188898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory machinery for the functional dystroglycan glycosylation.
    Kondo Y; Okajima T
    J Biochem; 2023 Apr; 173(5):333-335. PubMed ID: 36760122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
    Cataldi MP; Lu P; Blaeser A; Lu QL
    Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
    Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
    Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
    Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
    Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
    Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
    Elife; 2021 Jan; 10():. PubMed ID: 33513091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.
    Beltrán D; Anderson ME; Bharathy N; Settelmeyer TP; Svalina MN; Bajwa Z; Shern JF; Gultekin SH; Cuellar MA; Yonekawa T; Keller C; Campbell KP
    Skelet Muscle; 2019 May; 9(1):11. PubMed ID: 31054580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
    Tamura JI; Tamura T; Hoshino S; Imae R; Kato R; Yokono M; Nagase M; Ohno S; Manabe N; Yamaguchi Y; Manya H; Endo T
    ACS Chem Biol; 2022 Jun; 17(6):1513-1523. PubMed ID: 35670527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition.
    Praissman JL; Willer T; Sheikh MO; Toi A; Chitayat D; Lin YY; Lee H; Stalnaker SH; Wang S; Prabhakar PK; Nelson SF; Stemple DL; Moore SA; Moremen KW; Campbell KP; Wells L
    Elife; 2016 Apr; 5():. PubMed ID: 27130732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
    Imae R; Manya H; Tsumoto H; Miura Y; Endo T
    J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
    van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
    Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model.
    Wu B; Drains M; Shah SN; Lu PJ; Leroy V; Killilee J; Rawls R; Tucker JD; Blaeser A; Lu QL
    PLoS One; 2022; 17(12):e0278482. PubMed ID: 36454905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
    Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
    Elife; 2023 Feb; 12():. PubMed ID: 36723429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.
    Cataldi MP; Vannoy CH; Blaeser A; Tucker JD; Leroy V; Rawls R; Killilee J; Holbrook MC; Lu QL
    Mol Ther; 2023 Dec; 31(12):3478-3489. PubMed ID: 37919902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a novel monoclonal antibody against truncated glycoforms of α-dystroglycan lacking matriglycans.
    Yamasaki F; Umezawa F; Sensui T; Anzo M; Abo H; Kuo CW; Khoo KH; Kato K; Yagi H; Kawashima H
    Biochem Biophys Res Commun; 2021 Nov; 579():8-14. PubMed ID: 34583196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Break Down of the Complexity and Inconsistency Between Levels of Matriglycan and Disease Phenotype in FKRP-Related Dystroglycanopathies: A Review and Model of Interpretation.
    Lu QL; Holbrook MC; Cataldi MP; Blaeser A
    J Neuromuscul Dis; 2024; 11(2):275-284. PubMed ID: 38277301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.
    Hoshino S; Manya H; Imae R; Kobayashi K; Kanagawa M; Endo T
    J Biochem; 2024 Mar; 175(4):418-425. PubMed ID: 38140954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POMK regulates dystroglycan function via LARGE1-mediated elongation of matriglycan.
    Walimbe AS; Okuma H; Joseph S; Yang T; Yonekawa T; Hord JM; Venzke D; Anderson ME; Torelli S; Manzur A; Devereaux M; Cuellar M; Prouty S; Ocampo Landa S; Yu L; Xiao J; Dixon JE; Muntoni F; Campbell KP
    Elife; 2020 Sep; 9():. PubMed ID: 32975514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.